


23	Octo	ber	2020
Equity	Re	sea	rch
research@arm	isecuri	ities.co	<u>m.ng</u>
	+234	1 2 7 0	1652

Rating	BUY
Price	<del>N</del> 15.95
FVE	<del>N</del> 21.40
52-week range	<del>N</del> 12.85 – <del>N</del> 35.60
Market Cap. ( <del>N</del> 'bn)	34.39
l-month Avg. Vol	1,202,376
Curr. PE	22.6x

### **GUINNESS** .NL –Price Trend



Analyst(s)

Temitayo Peters temitayo.peters@arm.com.ng

# Guinness Nigeria Plc. (GUINNESS.NL)

#### Stock report

## Surprising YoY growth in revenue

Guinness Nigeria's Q1 2021 result revealed a pre-tax loss of  $\pm 0.32$  billion, an improved position from the loss of  $\pm 0.37$  billion reported in same period last year. The result was positive when compared to our estimates, stemming from higher than expected revenue as well as FX gains reported over the period. While we anticipated a QoQ improvement in sales, following the relaxation of the lockdown restrictions, the YoY improvement came as a surprise as the company implemented a price hike at the start of this calendar year. Over the review period, sales improved by 259% QoQ and 11.6% YoY to  $\pm 30.02$  billion.

- Higher costs lead to gross profit decline: A 46% YoY decline in export revenue to N0.37 billion means that the 11.6% YoY growth in overall revenue was driven solely by increased sales in Nigeria (+13%YoY). However, cost of sales rose 21.4% YoY (Q120: -0.2% YoY) to N23.01 billion which represents a faster rate of increase than the 11.6% rise in revenue. This translated to an 11.8% YoY decline in gross profit to N7.01 billion which gives a gross profit margin of 23.4% (Q120: 29.5%). Despite this lower gross profit, improved performances away from the topline meant that overall loss in Q121 was lower than in Q120
- OPEX declined sharply by 10.2% YoY (Q120: -3.4%YoY) to N6.63 billion led by falls in both admin costs (-7.9% YoY) and sales & distribution costs (-11.1% YoY). Combining that with other income of N0.21 billion gives us an EBIT of N0.59 billion, a 14% decline compared to the same period last year. EBIT margin is slightly lower at 2.0% compared to the 2.5% in Q120.
- Net finance cost declined by 14.1% YoY (Q120: +143.8%YoY) to N0.9 billion following a faster increase in finance income than finance costs. Finance income rose 96.9% led by a 132% rise in gains from FX re-measurement while finance costs rose 6.2%YoY. Though the company paid down its short-term debt to N13.28 billion (-42% QoQ), the FX losses booked on the \$23 million parent loan company drove the mild increase in finance cost.

- The balance sheet showed a 258% increase in cash to N18.88 billion between Q420 and Q121, which was driven by a 66% decline in trade receivables to N6.27 billion, the lowest we have seen it since 2013. This is in line with the policy announced last quarter of improving their credit risk, in particular we saw the amount due from related parties decline by 97%QoQ.
- **Buy recommendation maintained:** The performance this past quarter has increased optimism for FY21. However, the current unrest across Nigeria and the re-imposition of restrictions in advanced economies could affect sales over the upcoming festive period. on that note, we cautiously increased our overall revenue projections for FY21 based on higher domestic sales with exports coming in flat for the year. As a result we have raised our FVE rise by 15% to **N21.40** which, based on current market price, represents a **BUY** rating.

Summary of Result	s and Forecast	ts - <del>N</del> '000			
QUARTERLY					
Income Statement (₦'m) *	Q120	Q220	Q320	Q420	Q121
Revenue	26,898,779	41,428,478	27,691,248	8,357,510	30,024,212
COGS	18,953,797	29,521,905	16,740,144	5,830,108	23,013,178
Gross Profit	7,944,982	11,906,573	10,951,104	2,527,402	7,011,033
Operating Cost	7,382,745	9,190,416	9,432,244	4,153,486	6,631,857
Operating Profit	681,568	2,878,218	1,658,512	(1,540,294)	586,314
Net finance Income	(1,051,982)	(573,402)	(1,587,114)	(1,028,888)	(903,794)
РВТ	(370,414)	2,304,816	71,398	(2,569,182)	(317,480)
Tax	-	619,008	24,974	(5,138,806)	524,167
PAT	(370,414)	1,685,808	46,424	2,569,624	(841,647)
Balance Sheet ( <del>N</del> '000) * 	3M20	6M20	9M20	12M20	3M21
Fixed Assets	101,558,622	102,647,372	102,535,325	90,173,043	88,995,696
Inventory	28,240,874	19,997,066	24,769,920	26,426,253	20,678,601
Receivables	25,763,240	31,555,536	23,605,174	18,718,953	6,274,302
Cash & other bank balances	14,939,598	11,420,668	9,064,024	5,271,224	18,884,042
Total Assets	171,541,010	166,105,438	160,749,207	144,145,581	138,347,785
Liabilities					
Payables	171,541,010	166,105,438	160,749,207	144,145,581	138,347,785
Non-current Liabilities	22,887,635	22,892,346	23,364,204	10,509,465	10,643,504
Total liabilities	82,850,961	79,058,965	73,656,308	71,107,441	66,151,292
Shareholders' fund	88,690,049	87,046,473	87,092,899	73,038,140	72,196,494
Key Ratios	Q120	Q220	Q320	Q420	Q121
Gross Margin	29.5%	28.7%	39.5%	30.2%	23.4%
EBIT Margin	2.5%	6.9%	6.0%	-18.4%	2.0%
PBT Margin	-1.4%	5.6%	0.3%	-30.7%	-1.1%
PATt Margin	-1.4%	4.1%	0.2%	30.7%	-2.8%
EPS	(0.17)	0.77	0.02	1.17	(0.38)

#### **ARM ratings and recommendations**

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

ТОР 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% - 20 %	NEUTRAL	5% - 20%
NEUTRAL	0% — 10%	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

RECOMMENDATION KEY		
Rating	Recommendation	
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations	
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight	
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reasonable portfolio constraints	
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting	
SELL	Sell-off security completely from portfolio	

Copyright © 2020 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.